EN DE
Watch SillaJen Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

SillaJen Inc (215600) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of SillaJen Inc stock KRW 1,388, price KRW 1,998, that is 30.6% below the price, quality 39 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7215600008

SI SillaJen Inc logo Thin data Nov 10, 2026

SillaJen Inc

215600 · KQ
Expensive, weak quality

Our calculation puts a fair price 31% below what the stock costs today.

Low debt
Mixed Growth (revenue 5y +40.8 %/yr in KRW)
Mixed vs. peers (4/8)
Fair value 1,388 KRW · Overvalued
Quality 39/100
Negative free cash flow
Narrow moat 16/100
Thin data
Estimate
Watch SillaJen Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

71,296 KRW 1,844 KRW Fair Value 1,388 KRW Jan 2019 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 1,844 KRW – 71,296 KRW · fair‑value band 1,041 KRW – 1,734 KRW · the 1,998 KRW price screens above the 1,388 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow SillaJen in your weekly email

Every Wednesday you see whether SillaJen is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

SillaJen, Inc., together with its subsidiaries, engages in developing technologies and products using genetic engineering in South Korea.

Show moreShow less

Its clinical pipeline includes Pexa-Vec, which is in phase 2 clinical trial to treat renal cell carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors.

The company also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-600 Series and JX-970 to treat solid tumors and is in preclinical trial. In addition, it operates in biotechnology research industry.

SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.

Stock analysis

SillaJen Inc (215600) currently trades at 1,998 KRW, while our estimate is 1,388 KRW, 31% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 1,041 KRW (bear) to 1,734 KRW (bull), the price of 1,998 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

SillaJen Inc reported revenue of 9.2B KRW in FY2025 versus 254M KRW in FY2021, a compound +145.4%/yr. Reported net income was −24.2B KRW in FY2025.

Key figures

Market cap 276B KRW (≈ $206M) Micro · P/S ratio 27.6 · EPS (TTM) −174.01 KRW · Return on equity −21.5% · Return on assets (EBIT) −21.6% (5-year average) · Operating margin −276% · Revenue (TTM) 10.8B KRW · Revenue growth (YoY) −6.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (medium confidence).

What moves the price

The share trades about 60% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −31%, 215600 screens richer than that median.

Fair Value

Bear 1,041 KRW Fair Value 1,388 KRW Bull 1,734 KRW
Price 1,998 KRW · Downside -30.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 79
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 79
Debt, balance sheet and risk of trouble
Investment 40
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 15
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 37
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 29/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+134.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.8%
Start year 2020 (pandemic). Over 10 years: +17.7% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,767.5% (2020) → −285.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

215600 screens overvalued: fair value 31% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare SillaJen Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 867 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 39 · Below median
Fair Value upside −29.2% · Below median
Profitability
Return on assets −20.7% · Above median
Growth and dividend
Revenue growth (quarter YoY) −6.2% · Below median
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.48× · Cheaper than median
P/S (12 months) 25.38× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 19

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $919.96 $1,275 +39% vs 215600
Samsung Biologics Co 207940 1,510,000 KRW 1,661,000 KRW +10% vs 215600
Vertex Pharmaceuticals Incorporated VRTX $550.87 $601.80 +9% vs 215600
Genmab A/S GMAB kr 3,661 kr 3,880 +6% vs 215600
argenx SE ARGX $962.27 $908.40 −6% vs 215600
CSL Limited CSL A$200.73 A$181.40 −10% vs 215600
BeOne Medicines AG 6160 HK$248.20 HK$152.80 −38% vs 215600
Roivant Sciences Ltd ROIV $40.67 $17.39 −57% vs 215600
Celltrion, Inc 068270 210,000 KRW 74,945 KRW −64% vs 215600
Royalty Pharma plc RPRX $68.77 $19.01 −72% vs 215600

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SillaJen Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "SillaJen Inc Fair Value". https://www.fairvalue-calculator.com/stock/215600

Frequently asked questions

Is SillaJen Inc (215600) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 1,388 KRW versus a price of 1,998 KRW, about 31% lower (overvalued).
What is the fair value of 215600?
Our estimate for SillaJen Inc is 1,388 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 1,998 KRW.
What is the quality score of 215600?
SillaJen Inc has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SillaJen Inc (215600)?
Our calculated price target is the estimate of 1,388 KRW (as of Nov 10, 2026). Cautious scenario 1,041 KRW, optimistic scenario 1,734 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the SillaJen Inc stock forecast for 2026?
Our estimate puts fair value at 1,388 KRW, about 31% lower versus a price of 1,998 KRW (overvalued). Cautious scenario 1,041 KRW, optimistic scenario 1,734 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of SillaJen Inc (215600)?
SillaJen Inc reported trailing-twelve-month revenue of about 10.8B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of SillaJen Inc (215600)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SillaJen Inc it is 1,388 KRW per share (as of Nov 10, 2026), against a price of 1,998 KRW.
Is SillaJen Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 215600 trades above its calculated fair value: price 1,998 KRW, fair value 1,388 KRW, a gap of about −31% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 215600?
No. The price is what the market pays today (1,998 KRW); the fair value is what the company's own numbers justify (1,388 KRW). For SillaJen Inc the two are 610.43 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is SillaJen Inc worth?
The market values SillaJen Inc at about 276B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 1,998 KRW; our models calculate a fair value of 1,388 KRW per share.
What do the bullish and bearish scenarios say about 215600?
Our models span a range for SillaJen Inc: cautious scenario 1,041 KRW, base 1,388 KRW, optimistic 1,734 KRW per share (as of Nov 10, 2026, price 1,998 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of SillaJen Inc (215600)?
Balance-sheet figures for SillaJen Inc (as of Nov 10, 2026): return on equity −21.5%, debt of 0.01 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is 215600 from its 52-week high?
SillaJen Inc trades at 1,998 KRW, about 60% below its 52-week high of 4,975 KRW and 8% above the low of 1,844 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 1,388 KRW is for.
Which stocks are comparable to SillaJen Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SillaJen Inc stock attractive at the current price?
The data as of Nov 10, 2026: price 1,998 KRW, calculated fair value 1,388 KRW (−31%), Quality Score 39/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. SillaJen Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SillaJen Inc (215600)?
The closing price on Nov 10, 2026 was 1,998 KRW. Our estimate is 1,388 KRW, about 31% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SillaJen Inc right now?
The price sits above even our optimistic bull case (1,734 KRW). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of SillaJen Inc

How large is the market capitalisation of SillaJen Inc (215600)?
The market capitalisation of SillaJen Inc is 276B KRW (≈ $206M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SillaJen Inc (215600)?
The price-to-sales ratio of SillaJen Inc is 27.6 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SillaJen Inc (215600)?
Earnings per share at SillaJen Inc are −174.01 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of SillaJen Inc (215600)?
The return on equity (ROE) of SillaJen Inc is −21.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SillaJen Inc (215600)?
On an EBIT basis the return on assets of SillaJen Inc is −21.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SillaJen Inc (215600)?
The operating margin of SillaJen Inc is −276% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SillaJen Inc (215600)?
Revenue at SillaJen Inc is growing −6.2% versus a year earlier (3y avg +22.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does SillaJen Inc (215600) generate?
The free cash flow of SillaJen Inc is −26.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does SillaJen Inc (215600) carry?
The net debt of SillaJen Inc is 1.8B KRW (fiscal year 2022). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch SillaJen Inc in the live analysis

One click puts SillaJen Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.